Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Formation of the Platelet Plug01:22

Formation of the Platelet Plug

7.8K
The platelet phase, the second stage of hemostasis, commences around 15-20 seconds after an injury. It follows and overlaps with the vascular phase, during which blood vessels constrict to minimize blood loss.
As the injured blood vessel contracts, endothelial cells undergo contraction, revealing collagen fibers in the basement membrane and underlying connective tissue. Furthermore, the plasma membrane of endothelial cells becomes adhesive, preparing the site for platelet adhesion. Platelets...
7.8K
Structure and Function of Platelets01:18

Structure and Function of Platelets

2.2K
The cell fragments known as platelets are disc-shaped, with an average diameter of about 3 μm and a thickness of roughly 1 μm. They play a crucial role in the body's vascular clotting system, which also involves plasma proteins, blood cells, and blood vessel tissues.
Platelets are continually replenished, circulating in the bloodstream for 9-12 days before being removed by phagocytes, primarily in the spleen. A microliter of circulating blood contains between 150,000 and 450,000...
2.2K
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors01:20

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

773
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
773
Anticoagulant Drugs: Low-Molecular-Weight Heparins01:30

Anticoagulant Drugs: Low-Molecular-Weight Heparins

1.1K
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
1.1K
Disorders of Hemostasis01:24

Disorders of Hemostasis

1.4K
Hemostasis, the process that stops bleeding after a blood vessel injury, is crucial for maintaining the integrity of the circulatory system. However, disorders of hemostasis can disrupt this delicate balance, leading to either excessive clotting or bleeding. These disorders can be broadly classified into thromboembolic disorders and bleeding disorders.
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
1.4K
Introduction to Hemostasis01:05

Introduction to Hemostasis

10.2K
Hemostasis is a complex physiological process that prevents excessive bleeding when a blood vessel is injured. It's crucial for maintaining the integrity of the circulatory system, as it ensures that our blood remains fluid while still within the vascular network and yet clots to prevent blood loss upon vessel injury.
The three phases of hemostasis involve many clotting factors present in plasma and several substances released by platelets and injured tissue cells. It is a fast, localized,...
10.2K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Multifactorial strategies for the prevention of the risks of ulceration in patients affected by diabetic foot: a no-profit, multicentre, clinical trial protocol.

BMJ open·2026
Same author

Novel mechanisms linking platelet activation to antiphospholipid syndrome.

Current opinion in immunology·2026
Same author

Reply to the Comment: Revisiting Platelet-associated Tissue Factor: Methodological Concerns in Flow Cytometry Detection.

Thrombosis and haemostasis·2026
Same author

Correlation between frailty status, surgical access, and outcomes in older adults with valvular heart disease undergoing cardiac surgery.

npj aging·2026
Same author

Erratum: Flow Cytometry Analysis of Tissue Factor Expression in Human Platelets.

Journal of visualized experiments : JoVE·2026
Same author

Mitochondrial permeability transition pore desensitization by a novel dispiranic derivative prevents cardiac reperfusion injury.

Redox biology·2026

Related Experiment Video

Updated: Oct 24, 2025

Procoagulant Platelet Characterization by Measuring Phosphatidylserine Exposure and Microvesicle Release from Human Purified Platelets
05:49

Procoagulant Platelet Characterization by Measuring Phosphatidylserine Exposure and Microvesicle Release from Human Purified Platelets

Published on: November 29, 2024

814

Alterations in platelets during SARS-CoV-2 infection.

Marta Brambilla1, Paola Canzano1, Alessia Becchetti1

  • 1Unit of Cell and Molecular Biology in Cardiovascular Diseases, Centro Cardiologico Monzino IRCCS, Milan, Italy.

Platelets
|August 13, 2021
PubMed
Summary

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection alters platelet activation, promoting thrombosis. Targeting this platelet activation with drugs like aspirin may offer therapeutic benefits for COVID-19 patients.

Keywords:
Antiplatelet drugsCOVID-19coagulationplateletsthrombosis

More Related Videos

Comprehensive Analysis of Procoagulant Platelets Exhibiting Features of Necrosis, Apoptosis and Platelet Activation
04:37

Comprehensive Analysis of Procoagulant Platelets Exhibiting Features of Necrosis, Apoptosis and Platelet Activation

Published on: May 23, 2025

771
Microfluidics in Assessing Platelet Function
06:47

Microfluidics in Assessing Platelet Function

Published on: November 8, 2024

1.2K

Related Experiment Videos

Last Updated: Oct 24, 2025

Procoagulant Platelet Characterization by Measuring Phosphatidylserine Exposure and Microvesicle Release from Human Purified Platelets
05:49

Procoagulant Platelet Characterization by Measuring Phosphatidylserine Exposure and Microvesicle Release from Human Purified Platelets

Published on: November 29, 2024

814
Comprehensive Analysis of Procoagulant Platelets Exhibiting Features of Necrosis, Apoptosis and Platelet Activation
04:37

Comprehensive Analysis of Procoagulant Platelets Exhibiting Features of Necrosis, Apoptosis and Platelet Activation

Published on: May 23, 2025

771
Microfluidics in Assessing Platelet Function
06:47

Microfluidics in Assessing Platelet Function

Published on: November 8, 2024

1.2K

Area of Science:

  • Immunology
  • Hematology
  • Virology

Background:

  • Coronavirus disease 2019 (COVID-19), caused by SARS-CoV-2, is a global pandemic.
  • SARS-CoV-2 infection is associated with significant inflammation and thrombosis.
  • Altered platelet activation is a key feature in COVID-19 pathogenesis.

Purpose of the Study:

  • To investigate the specific mechanisms of platelet activation in SARS-CoV-2 infection.
  • To explore the potential of targeting platelet activation as a therapeutic strategy for COVID-19.
  • To evaluate the efficacy of antithrombotic drugs, such as aspirin, in managing COVID-19-associated thrombosis.

Main Methods:

  • Analysis of platelet aggregation patterns in COVID-19 patients.
  • Assessment of platelet-leukocyte interactions.
  • Quantification of procoagulant factors, including TF-positive platelets and microvesicles.
  • Review of existing therapeutic strategies and drug candidates.

Main Results:

  • SARS-CoV-2 infection uniquely promotes platelet-leukocyte aggregates over platelet-platelet aggregates.
  • Elevated levels of tissue factor (TF)-positive platelets and microvesicles indicate increased procoagulant potential.
  • Anti-inflammatory drugs (e.g., tocilizumab) and antithrombotic agents (e.g., aspirin) show promise.

Conclusions:

  • Platelet activation plays a critical role in the inflammatory and thrombotic processes of COVID-19.
  • Therapeutic interventions targeting specific platelet activation pathways are warranted.
  • Antiplatelet therapy, including aspirin, represents a potential treatment avenue for COVID-19 patients with thrombotic complications.